Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) announced top-line results from a Phase IIa clinical study of SerdaxinTM, its major depressive disorder (MDD) drug candidate. The randomized, double blind, placebo controlled and dose ranging study enrolled 77 patients and was conducted at multiple U.S. sites to assess Serdaxin’s safety and preliminary efficacy. The study showed that patients ages 18-65 with MDD exhibited clinically meaningful improvement over baseline in symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score. A marked clinical response was observed within two weeks in patients taking Serdaxin. Additionally, a significantly lower drop-out rate among patients taking Serdaxin compared with those patients taking a placebo was observed (<20% treatment groups vs. >50% placebo group).